NCT02213484 is a clinical trial in Marfan Syndrome, sponsored by University of Colorado, Denver.

Who is sponsoring NCT02213484?

NCT02213484 is sponsored by University of Colorado, Denver.

What condition does NCT02213484 study?

NCT02213484 studies Marfan Syndrome, Loeys-Dietz Syndrome, Thoracic Aortic Aneurysm and Dissection Syndromes, Ehlers-Danlos Type IV Syndrome, Turner Syndrome.

Is NCT02213484 still recruiting?

NCT02213484 is currently completed. Last updated 15 March 2017.

Last reviewed 2017-03-15 · How we verify

NCT02213484

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes

Completed Last updated 15 March 2017

What this trial tests

trial in Marfan Syndrome in 20 participants. Completed in 1 July 2016.

Timeline

1 July 2014

Primary endpoint
1 July 2016

1 July 2016

Quick facts

Lead sponsor	University of Colorado, Denver
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20
Start date	1 July 2014
Primary completion	1 July 2016
Estimated completion	1 July 2016
Sites	2 locations across United States

Conditions studied

Marfan Syndrome — all drugs for Marfan Syndrome →
Loeys-Dietz Syndrome — all drugs for Loeys-Dietz Syndrome →
Thoracic Aortic Aneurysm and Dissection Syndromes — all drugs for Thoracic Aortic Aneurysm and Dissection Syndromes →
Ehlers-Danlos Type IV Syndrome — all drugs for Ehlers-Danlos Type IV Syndrome →

Sponsor

University of Colorado, Denver

Who can join

Adults 30 Days to 60, any sex, with Marfan Syndrome or Loeys-Dietz Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to determine whether specific patterns of circulating micro-ribonucleic acids (miRNAs) are associated with aortic aneurysm and dissection in patients with hereditary aortopathy syndromes. The most common of these syndromes is Marfan Syndrome (MFS), but several other recognized aortopathy syndromes are well characterized. The investigators propose the use of a simple blood test, from which miRNA profiles can be measured in individuals with aortopathy syndromes to be compared with miRNAs observed in a control population that has no known predisposition for aortic disease. The investigators hypothesize that microRNA profiles in individuals with Marfan syndrome, and related disorders, will be distinct from those seen in a control group. The investigators predict that up- or down-regulation of certain miRNAs will correlate with the presence and severity of aortic aneurysm, responses to medical therapy, and ultimately could be used to determine when an individual may be at risk of dissection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Novel epigenetic-based therapies useful in cardiovascular medicine.
Napoli C, Grimaldi V, De Pascale MR, Sommese L, et al · · 2016 · cited 34× · PMID 26981216 · DOI 10.4330/wjc.v8.i2.211

Verify or expand the search:

Other recruiting trials for Marfan Syndrome

Currently open trials in the same condition.

NCT06546137 — National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Un · recruiting
NCT05809323 — Marfan Syndrome Moderate Exercise Trial II · NA · recruiting
NCT04970459 — Biological Collection for Marfan and Related Syndromes · recruiting
NCT03440697 — Pathogenetic Basis of Aortopathy and Aortic Valve Disease · active not recruiting

Other University of Colorado, Denver trials

Trials by the same sponsor.

NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02213484 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
Last refreshed: 15 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02213484.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing